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The Hebrew University, Jerusalem, Israel
Cancer development is dependent on intrinsic cellular changes as well as inflammatory 
factors in the tumor macro and microenvironment. The inflammatory milieu nourishes the 
tumor and contributes to cancer progression. Numerous studies, including ours, have 
demonstrated that the tumor microenvironment is immunosuppressive, impairing the 
anticancer immune responses. Chronic inflammation was identified as the key process 
responsible for this immunosuppression via induction of immature myeloid-derived 
suppressor cells (MDSCs). Upon a prolonged immune response, MDSCs are polarized 
toward immunosuppressive cells meant to control the exacerbated immune response. 
In cancer, the chronic inflammatory response renders the MDSCs harmful. Polarized 
MDSCs suppress T-cells and natural killer cells, as well as antigen-presenting cells, 
abrogating the beneficial immune response. These changes in the immunological milieu 
could also lead to high frequency of mutations, enhanced cancer cell stemness, and 
angiogenesis, directly supporting tumor initiation, growth, and spreading. The presence 
of MDSCs in cancer poses a serious obstacle in a variety of immune-based therapies, 
which rely on the stimulation of antitumor immune responses. Cumulative data, including 
our own, suggest that the selection of an appropriate and effective anticancer ther-
apy must take into consideration the host’s immune status as well as tumor-related 
parameters. Merging biomarkers for immune monitoring into the traditional patient’s 
categorization and follow-up can provide new predictive and diagnostic tools to the 
clinical practice. Chronic inflammation and MDSCs could serve as novel targets for ther-
apeutic interventions, which can be combined with conventional cancer treatments such 
as chemotherapy, radiotherapy, and cancer cell-targeted and immune-based therapies. 
Intervention in environmental and tumor-specific inflammatory mechanisms will allow 
better clinical management of cancer toward more efficient treatment.
Keywords: cancer, MDSC, inflammation, immunosuppression, immunotherapy, chemotherapy, immune 
monitoring, biomarkers
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iNTRODUCTiON
While some cancers are triggered by intrinsic cellular changes 
such as germ-line mutations, the majority of tumors are caused 
by acquired somatic mutations due to alterations in homeostatic 
environmental factors. In many cases, tumor development is 
associated with nutritional and environmental factors, generated 
by chronically occurring pathologies such as infections, autoim-
mune disorders, metabolic diseases, and more. The common 
denominator of these processes is chronic inflammation, which is 
an abnormal and sustained form of a protective response. It starts 
as an acute inflammation; a beneficial response resolving insults 
such as newly encountered pathogens or transformed cells. 
However, when the stimuli that induce the immune response 
could not be cleared, a continued inflammatory response evolves. 
The prolonged response leads to loss of tissue homeostasis, result-
ing in a condition similar to unhealed wounds (1). This type of 
dysregulated responses occur at higher rates in cases of cancer, 
where transformed cells in conjunction with proinflammatory 
cells and factors result in tumor development and progression (2). 
On the one hand, growing tumors intensify the proinflammatory 
conditions that directly nourish their own growth and spreading. 
On the other hand, the prolonged response also creates an immu-
nosuppressive environment by recruiting an array of suppressor 
cells and factors that enable escape of the tumor from immune 
surveillance (3).
In this review, we highlight the regulatory checkpoints con-
trolled by immunosuppressive cells and factors in the tumor 
micro and macro environments, focusing on MDSCs: immuno-
suppressive cells which play a critical role in maintaining normal 
homeostasis and when polarized under chronic inflammatory 
conditions could skew the environment toward supporting tumor 
development and spreading.
iMMUNe SYSTeM HOMeOSTASiS
Immune homeostasis is the body’s tightly regulated network of 
physiological checkpoints and balances that enables controlled 
defensive responses against pathogens or altered self-cells. In 
healthy individuals, an immune challenge by foreign or self-
created insults initiates a cascade of appropriate responses that 
restore the tissue to its steady state. Homeostasis is transiently 
imbalanced when an acute inflammatory response is initi-
ated to counteract a danger signal. In this regard, the acute 
inflammation is beneficial, as innate and adaptive immune 
cells are recruited and activated as long as the insult exists. 
Once the insult has been removed, the response is resolved 
and homeostasis is reconstituted, while enriching the host 
with a reservoir of memory and regulatory cells. These 
immune response cycles depend on a subtle balance between 
the effector and regulatory arms of the immune system and 
their capacity to clear the initial stimulus. The intricate cross 
talk between immune cells and soluble factors (cytokines and 
chemokines) ensues execution of pro- and anti-inflammatory 
responses at the appropriate time and location, thus preventing 
excessive and harmful immune activation. When the immune 
homeostasis is continuously disrupted, the host’s immune 
response can become hypo- or hyperactive. A compromised 
immune response poses severe immune deficiency-based 
complications, such as opportunistic infections and cancer. In 
contrast, autoimmune disorders are on the overactive side of 
the homeostatic spectrum. Thus, the maintenance of fine-tuned 
regulatory and effector immune functions is at the forefront of 
a balanced immune homeostasis.
Since excessive immune responses can be deleterious, 
regulatory mechanisms have evolved to suppress and resolve 
immune responses. There are several immunosuppres-
sive cell populations, which regulate immune homeostasis 
by restraining aberrant or excessive immune responses. 
CD4+CD25highFoxp3+ regulatory T cells (Tregs) are essential 
for the maintenance of immune homeostasis, as their dysfunc-
tion leads to the appearance of widespread, fatal, immune-
mediated diseases (4). Regulatory dendritic cells (rDCs) have 
the ability to regulate or inhibit T-cell activation and induce/
promote Treg development and expansion (5, 6). Immature 
DCs induce tolerance due to inefficient antigen presentation 
and lack of costimulatory molecules (5, 7, 8). M2 macrophages 
play a role in wound healing by producing growth and angio-
genic factors. However, they also have immunoregulatory 
activities as they produce regulatory cytokines (TNF-α, IL-1, 
IL-6, IL-10, and TGF-β) and overexpress arginase-1 (ARG-1) 
(9–12).
Cumulative evidence indicates that the most “powerful players” 
in turning off the immune response are immature myeloid cells 
(IMCs), also termed non-polarized or “resting” myeloid-derived 
suppressor cells (MDSCs). These cells were demonstrated to be 
tolerogenic and capable of suppressing immune system activi-
ties. In healthy individuals, these immature myeloid progenitors 
are retained in the bone marrow (BM) where they maintain a 
suppressive environment (13), most likely for preserving BM 
homeostatic niches. MDSCs display the capacity to migrate 
to the periphery and differentiate into mature macrophages, 
DCs, and neutrophils while losing their suppressive phenotype. 
Mouse MDSCs are characterized by CD11b+Gr1+ and can be 
subdivided into monocytic (CD11b+Ly6G-Ly6Chigh), which lack 
DC and macrophage markers (CD11c−, F4/80−, respectively) 
(14) and granulocytic (CD11b+Ly6G+Ly6Clow) cells. The identity 
of human MDSCs is more intricate and based on several markers 
(CD11b+CD33+HLA-DR−), which could be further divided into 
monocytic (CD14+CD11b+CD33+HLA-DR−) and granulocytic 
(CD15+CD11b+CD33+HLA-DR−) phenotypes. Both granulocytic 
and monocytic subpopulations have been shown to be suppres-
sive, especially the latter. However, the majority of MDSCs are 
granulocytic, making up in numbers for their milder suppressive 
ability (15). Under normal conditions, about 50–60% of the resi-
dent cells in mouse BM are resting Gr1+CD11b+ MDSCs, which 
exhibit a basal suppressive activity. Interestingly, mature T-cells 
that are occasionally circulating through the normal BM become 
reversibly dysfunctional, similar to peripheral T-cells during 
chronic inflammation (13). Under normal steady-state condi-
tions in mice, MDSCs are also found in the spleen (3–5%) and in 
the peripheral blood (~10%) (3), displaying a basal immunosup-
pressive activity as well, most likely controlling homeostasis and 
resolving acute immune responses.
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DiSRUPTeD iMMUNe HOMeOSTATiC 
eNviRONMeNT BY A DeveLOPiNG 
CHRONiC iNFLAMMATiON
Chronic inflammation induces MDSC 
Polarization and Accumulation
Chronic inflammation develops when pathogenic or self-aberrant 
antigenic insults (e.g., cancer cells) are not resolved. The inflam-
matory immune response proceeds, albeit failing to eliminate 
the antigenic stimuli. The generated conditions are characterized 
by an influx of proinflammatory cells of the innate and adaptive 
immune systems. Such cells secrete cytokines, chemokines, and 
soluble factors that eventually create micro and macro environ-
ments that support tumor initiation and development. In parallel, 
the generated chronic inflammatory environment constantly 
recruits the regulatory arm of the immune system to resolve and 
control the inflammatory response. The continuous activity of 
the immune system together with the recruitment of inhibitory 
cells/factors eventually induces a general immunosuppression of 
T-cells and natural killer (NK) cells and in some cases of DCs. 
These indirectly support the tumor by enabling its escape from 
the immune effector functions (3).
The immunosuppressive conditions generated in the course 
of chronic inflammation begin with the induction of MDSC 
polarization: turning the cells into highly suppressive MDSCs, 
while their differentiation is arrested, maintaining them in an 
immature state. Polarized MDSCs expand in the BM, accumulate 
in the periphery, and invade the local inflammatory sites, where 
they confer a systemic and site-specific immunosuppression. It is 
not yet fully clear how exactly resting MDSCs convert into harm-
ful immunosuppressive MDSCs. However, it is well established 
that under pathological conditions, increasing accumulation of 
growth factors [GM-CSF and VEGF (16)], chemokines [CXCL12 
(17) and CCL2 (16)], and cytokines [TNF-α, IFN-γ, IL-1β, IL-6, 
and TGF-β (18)] accelerate MDSC expansion in the BM and 
accumulation in the periphery. Polarized MDSCs reach the blood 
stream, spleen, and sites of inflammation, as evident in various 
chronic pathologies such as inflammatory bowel diseases (IBD) 
and various types of cancer. They accumulate as well during 
bacterial infections such as Helicobacter pylori (19), Salmonella 
enterica serovar Typhimurium (20), and Staphylococcus aureus 
(21) and in parasitic infections such as Schistosoma japonicum 
(22). Interestingly, MDSCs do not enter peripheral lymph nodes, 
making them protected from the suppressive environment (13), 
unless metastases are evident in the lymph nodes (23).
We have recently shown that TNF-α plays a critical role in 
MDSC accumulation and suppressive function as it leads to 
myeloid cell differentiation arrest, which is accompanied by a 
specific polarization of these cells toward an immunosuppressive 
phenotype, inducing dysfunction of effector immune cells (18). 
TNF-α is generated by a variety of immune and non-immune cells 
such as T-cells, NK cells, macrophages and tumor cells, endothe-
lial cells, mast cells, neurons, and fibroblasts (24). Interestingly, 
MDSCs themselves produce high levels of TNF-α, creating a 
positive autocrine and paracrine feedback that enhances their 
own polarization and accumulation. In addition to TNF-α, there 
is a variety of proinflammatory cytokines such as IL-1β, IL-6, and 
Type I and II interferons that are involved in establishing a pro-
inflammatory environment. Such cytokines are produced upon 
recognition of pathogenic or endogenous ligands by Toll-like 
receptors (TLRs) expressed on various immune cells including 
MDSCs. Our group had previously described a mechanism in 
which persistent TLR activation by a single ligand was sufficient 
to induce MDSC accumulation and immunosuppression, similar 
to a pathology characterized by chronic inflammation. In this 
model, usually non-virulent danger-associated molecular pat-
terns (DAMPs), such as LPS (TLR4), zymosan (TLR2), poly I:C 
(TLR3), or unmethylated CpG DNA (TLR9), induced a prolonged 
TH1 response accompanied by increased production of TNF-α 
and IFN-γ (25) (Figure 1A).
Myeloid-derived suppressor cell polarization is accompanied 
not only by their differentiation arrest but also by their enhanced 
immunosuppressive phenotype as reflected by the elevated activ-
ity of arginase-1 (ARG-1) and inducible nitric oxide synthase 
(iNOS), along with enhanced production of nitric oxide (NO) 
and reactive oxygen species (ROS). These effects are further 
enhanced by TNF-α (18, 26). The proinflammatory calcium bind-
ing S100 proteins, mainly S100A8/9, and their corresponding 
receptor, receptor for advanced glycation end products (RAGE), 
are upregulated in MDSCs in response to TNF-α. These proteins 
affect MDSCs in an autocrine and paracrine fashion to regulate 
MDSC polarization, accumulation, and differentiation arrest in a 
STAT-3-dependent mechanism (18, 27, 28) (Figure 1B).
immune System Dysregulation in the 
Course of Chronic inflammation
The suppressive environment generated in the course of chronic 
inflammation is foremost generated by MDSCs. These cells were 
shown to directly abrogate the function of various effector cells 
of the innate and adaptive arms of the immune system while 
increasing the activity of regulatory mechanisms (Figures 1E,F).
T-Cell Dysfunction
We have demonstrated that chronically inflamed animals are more 
susceptible to viral infection due to dysfunction of the innate and 
adaptive immune systems. Mice with chronic inflammation were 
more sensitive to influenza infection associated with severely 
reduced survival rates (29). These results were further supported 
by the inability of both CD4+ and CD8+ T-cells to proliferate and 
produce IFN-γ in response to T-cell receptor (TCR) stimulation 
both in vivo and in vitro when cocultured with MDSCs (13, 18, 25, 
29). MDSCs induce T-cell dysfunction by an array of mechanisms 
and perhaps the most prominent among these is the direct down-
regulation of CD247 [the ζ chain of the T-cell antigen receptor 
complex (TCR)]. CD247 is a 16 kDa transmembrane subunit of 
the TCR, containing within its long intracellular domain, three 
immune tyrosine based activation motifs (ITAMs), which make 
it the main signaling subunit of the TCR. CD247 is expressed 
in all T-cells and is crucial for TCR-mediated T-cell activation 
and serves as the limiting factor for the TCR complex expres-
sion on the cell surface. CD247 is easily detected both in mouse 
and human leukocytes with a specific antibody by Western blot 
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or intracellular staining for flow cytometry (18, 29, 30). Under 
chronic inflammatory conditions, MDSCs induce lysosomal 
degradation of CD247 within the T-cells without affecting the 
surface levels of the remaining TCR subunits, leaving a function-
ally cryptic and inactive complex (29). This is a bystander effect 
causing dysfunction of all T-cells in an antigen non-specific man-
ner. However, this phenomenon is reversible, since elimination 
of the chronic stimulus and/or MDSCs or neutralization of the 
inflammatory environment allows recovery of CD247 and T-cell 
function (13). The mechanisms applied by MDSCs to induce 
CD247 downregulation are still unknown.
l-arginine consumption by MDSCs is another key factor 
in the induction of T-cell dysfunction, which is governed by 
increased activity of ARG-1 and iNOS, using l-arginine as 
their substrate. l-arginine depravation was shown to cause the 
downregulation of CD247 in T-cells in  vitro (31). A deeper 
FiGURe 1 | A vicious cycle of chronic inflammation and cancer is maintained by MDSCs. Cancer and chronic inflammation mutually support one another in 
multiple ways. The cycle begins with a chronic inflammatory response generated by any persistent insult, including cancer. The effector cell milieu is recruited and 
activated by DAMPs derived from the immunogenic insult and produces various proinflammatory signals (such as IL-1, IL-6, GM-CSF, TNF-α, IFNγ, VEGF, and 
PGE2) (A). The proinflammatory signals persist and induce polarization and accumulation of MDSCs, which transform the beneficial inflammatory response to 
deleterious chronic inflammation. The MDSCs create a positive loop, increasing their own polarization and expansion by production of TNF-α and S100A8/9 proteins 
(B). The oxidative stress created by the production of NO and ROS by the MDSCs in the inflammatory sites may cause DNA damage and somatic mutations, 
increasing the risk for tumor initiation (C). MDSCs directly support tumor progression by increasing angiogenesis, tumor cell stemness, and metastasis (D). The 
suppressive activity of MDSCs inhibits the effector function of T-, NK-, and dendritic cells, abrogating the antitumor beneficial response (e). MDSCs further suppress 
the immune response by inducing Tregs, which can also directly support tumor growth by producing RANKL (F). The deleterious inflammatory milieu and the tumor 
itself provide more proinflammatory factors, further enhancing MDSC accumulation. Moreover, necrosis at the tumor releases endogenous DAMPs, which could 
either start the cycle of chronic inflammation and MDSC accumulation or keep perpetuating it (A,G).
mechanism has been described showing that l-arginine 
withdrawal from the environment leads to a G0–G1 cell cycle 
arrest in T-cells in  vitro and a global reduction in protein 
synthesis in the cells (32). The enzymatic activity of iNOS is 
harmful to T-cell functions, as it generates NO that is respon-
sible for suppressive consequences such as disrupting Jak3 
and STAT5 activities (33), inhibition of MHC class II gene 
expression (34), and the induction of T-cell apoptosis (35). 
Nagaraj et  al. showed that nitration of tyrosine residues of 
molecules involved in the immunological synapse is induced 
by MDSCs in an antigen-specific manner. The nitration cor-
related with the interference of TCR-CD8 complex assembly 
on the plasma membrane and a reduced antigen-specific 
TCR-mediated proliferation and IFN-γ production (36). In 
addition, MDSCs express galactin 9, which binds to the T-cell 
immunoglobulin domain and mucin domain 3 (TIM3), which 
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is a negative regulator of TH1-cell responses on lymphocytes 
and induces T-cell apoptosis (37). MDSCs downregulate 
l-selectin (CD62L), a plasma membrane molecule necessary 
for the homing of naive T-cells to lymph nodes. This reduces 
the activation of CD4+ and CD8+ T-cells and inhibits homing 
to tumor draining lymph nodes (38).
NK-Cell Dysfunction
The suppressive environment generated by MDSCs in chronic 
inflammation leads to impaired NK-cell activity as well. 
Induction of chronic inflammation in mice prevents NK-cell-
mediated allograft rejection in vivo, while elimination of MDSCs 
restores their ability to kill the allogeneic cells (18). CD247 is 
also expressed in NK cells, serving as a central signaling subunit 
of the NK killing receptors NKp46, NKp30, and FcγRIII (CD16), 
and is downregulated by MDSCs under chronic inflammatory 
conditions (25). Its downregulation may be a major reason for 
NK-cell dysfunction during chronic inflammatory conditions, 
including cancer settings. MDSCs also induce downregulation of 
the killing receptor NKG2D in vivo and in vitro (39). In addition 
to NKG2D downregulation, NK cells cocultured with MDSCs 
had reduced cytotoxic activity and IFN-γ production in vitro. 
These effects were shown to be cell contact dependent and were 
reversed by blocking membrane-bound TGF-β1 expressed on 
MDSCs, while soluble TGF-β did not suppress NK-cell activ-
ity (39). Blocking of NKp30 in cocultures of human MDSCs 
and NK cells was shown to reduce the suppressive effect of the 
MDSCs (40).
Prevention of Dendritic Cell Maturation
Accumulating data show that tumor residing DCs can retain an 
immature phenotype and induce tolerance to tumor antigens 
(41, 42). VEGF and IL-10 secreted in the tumor microenviron-
ment constitutively activate STAT3 signaling in DCs, leading 
to downregulation of MHC class II molecules and costimula-
tory molecules, preventing DC maturation (43). Moreover, 
mature DC numbers inversely correlate with MDSC levels in 
cancer patients, suggesting that elevated MDSC levels, which 
are arrested at their immature stage, are prevented from dif-
ferentiating to DCs (42). It is still unclear whether MDSCs 
can directly inhibit DC maturation and activity or the effect 
is a part of the skewed myelopoiesis in chronic inflammation. 
However, S100A8/9 proteins overexpressed in embryonic stem 
cells inhibited their ability to differentiate into mature DCs, 
abrogating their ability to induce T-cell proliferation in  vitro 
(27). S100A8/9 proteins are highly expressed by MDSCs, sug-
gesting a possible direct effect of MDSCs on DC differentiation 
via this pathway.
Induction of Regulatory T-Cells
In addition to inhibiting immune effector cells, MDSCs have been 
shown to activate regulatory cells to further induce immunosup-
pression. MDSCs were shown to induce expansion of Tregs by 
producing IL-10 and TGF-β (44). Tregs induced by antigen-
loaded MDSCs caused induction of antigen-specific tolerance 
in a model of multiple myeloma. This mechanism, however, was 
independent of TGF-β (45).
THe AGGRAvATiNG CONSeQUeNCeS
Chronic inflammation Leads to Tumor 
initiation and Cancer Development
Cancer is characterized by stepwise accumulation of genetic 
and epigenetic alterations of genes. As a high-risk factor for 
cancer, chronic inflammatory responses produce great amount 
of mediators, including cytokines, reactive oxygen and nitrogen 
species (ROS and NO, respectively), and proteinases, which 
can induce genetic and epigenetic changes of cancer-associated 
genes and pathways. An increased risk for cancer has been 
linked with various pathologies characterized by chronic 
inflammation such as IBD, papillomavirus, hepatitis C virus, 
and H. pylori infections that are linked to colon, cervix, liver, and 
gastric cancer, respectively (46–48). Chronic inflammation has 
also been thought to support progression of tumors, which were 
initiated by a non-immune carcinogenesis. Non-inflammatory 
tumors would be cleared by immune surveillance while inflam-
matory tumors would create chronic inflammation, induce 
MDSC accumulation, and abrogate the antitumor immune 
response (26, 28, 49).
The highly reactive oxidative agents ROS and NO, produced 
in the inflammatory settings, have been shown to cause DNA 
damage and induce somatic mutations (50). It was shown that in 
the case of IBD and H. pylori infection, the generated conditions 
lead to genomic instability in the mucosal layer and epithelial 
fractions of the colon and stomach, respectively, leading to 
tumor initiation (51, 52). This effect may be greatly enhanced 
when chronic inflammation develops and increasing numbers 
of NO/ROS producing MDSCs accumulate (Figure  1C). The 
skewed inflammatory environment generated by MDSCs leads 
to an uncontrolled cellular and factors milieu, ensuing in the 
establishment of an optimal niche for cancer initiation, tumor 
microenvironment enrichment, and support of a malignant 
progression. Furthermore, inflammation also modulates the 
expression of miRNAs and epigenetic changes that not only 
regulate the expression of tumor-related proteins but also 
enhance the tumor-promoting inflammation-associated car-
cinogenesis (53, 54).
Chronic inflammation with its associated cells, cytokines, 
chemokines, and soluble factors not only supports tumor initia-
tion but also shapes the environment that nourishes the newly 
transformed cells as well as the progressive tumors to overgrow 
and invade. The effect could be direct, affecting the tumor cells 
or indirectly, by perpetuating an immunosuppressive environ-
ment. For example, MDSC levels were shown to correlate with 
serum VEGF levels in a mouse model of spontaneous mammary 
carcinoma (55). While MDSCs do not produce VEGF directly, 
they are affected by VEGF produced by almost all types of 
tumors (56). MMP9 produced by MDSCs has been suggested 
to augment VEGF production and enhance tumor vasculature, 
growth, and invasiveness in mouse models (57, 58). MDSCs have 
also been shown to increase metastasis by promoting formation 
of pre-metastatic niches and tumor cell invasion (59). Recently, 
MDSCs were shown to enhance the stemness of ovarian carci-
noma cells, also increasing their metastatic capabilities, making 
the tumors more aggressive (60). Induction of Tregs by MDSCs 
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in the settings of cancer and chronic inflammation provides 
another indirect mechanism that supports tumor progression, as 
tumor infiltrating Tregs have been shown to directly stimulate 
mammary cancer metastasis by interaction of receptor activator 
of NFκB (RANK) with RANK ligand on the Tregs (61). Apart 
from supporting tumor progression, cumulative data show that 
chronic inflammation itself may have continuous carcinogenic 
effects. A recent research has linked inflammation-induced 
transcription programs mediated by NFATc1-STAT3 complex to 
enhanced tumorigenicity in Kras G12D-mutant mice pancreatic 
tissue, while mutated Kras or an inflammatory response alone 
were insufficient to initiate cancer (62). Moreover, several inflam-
matory cytokines such as TNF-α, IL-6, TGF-β, and IL-10 have 
been shown to participate in both the initiation and progression 
of cancer. Proinflammatory cytokines such as TNF-α can induce 
DNA damage through ROS, which leads to tumor initiation. 
TGF-β can promote malignant transformation through epi-
thelial–mesenchymal transition (EMT) activation. Cytokines 
derived from CD4+ lymphocytes, such as IFN-γ, IL-10, and IL-17, 
can participate in epithelial barrier disruption, M2 phenotypic 
transitions of macrophages, and angiogenesis, respectively. 
Tumor growth and invasion are also favored by proinflamma-
tory cytokines that stimulate cell proliferation, reduce apoptosis, 
and enhance EMT and angiogenesis; the latter is facilitated by 
VEGF and IL-8. Anti-inflammatory cytokines, such as IL-10 and 
TGF-β, contribute to tumor immune evasion. Tumor-associated 
macrophages (TAM), tumor-infiltrating lymphocytes (TIL), and 
cancer-associated fibroblasts (CAF) secrete several factors that 
contribute to tumor growth and metastasis while maintaining 
the immunosuppressive milieu (63) (Figure 1D).
Tumor Development Perpetuates Chronic 
inflammation
Different tumors vary in their proinflammatory profile produced 
by both the tumor and the inflammatory milieu. In fact, some 
tumors start off as non-inflammatory, yet at a certain stage 
inflammation and MDSC accumulation is evident regardless.
Toll-like receptors and other pattern recognition receptors 
(PRRs) recognize endogenous danger signals as well as pathogen-
associated molecular patterns. High-mobility group box protein 
1 (HMGB1) and heat shock protein 60 (HSP60) have been 
shown to act as adjuvants activating APCs and inducing immune 
response (64–66). HMGB1 is a highly conserved vertebrate 
nuclear protein, and HSP60 is a highly conserved mitochon-
drial–cytosolic molecular chaperone. Both proteins are released 
to the extracellular matrix in necrotic tissue. Recently, HMGB1 
and HSP60 have been shown to directly affect growth of murine 
mammary carcinoma in vitro in a MyD88-dependent mechanism 
(67), suggesting that a TLR recognition pathway is involved.
Necrosis in cancer, occurring due to insufficient vasculariza-
tion and tissue damage in the tumor and its surroundings, results 
in accumulation of endogenous DAMPs in the tumor microen-
vironment. Similar to other TLR ligands, these DAMPs activate 
immune cells and induce a sustained TH1 response, leading to 
increased production of proinflammatory cytokines by tumor-
infiltrating leukocytes. The generated inflammation persists 
as long as the tumor is present, perpetuating a vicious cycle of 
chronic inflammation, MDSC accumulation, and immunosup-
pression, which in turn drive disease progression (Figure 1G).
Tumor-Derived Soluble Factors Drive 
MDSC Accumulation and Activation
The number and activity of the MDSCs in cancer correlates with 
disease progression, tumor load, and the severity and persistence 
of the associated inflammation (55, 68). Many tumors are capable 
of directly affecting MDSCs by secretion of proinflammatory 
cytokines.
VEGF, secreted by almost all tumors, induces neovasculariza-
tion in the tumor microenvironment and supports tumor growth. 
VEGF’s effect on immune cells also takes a major role in inducing 
immunosuppression. Activation of STAT3 by VEGF results in 
induction of tolerogenic immature DCs (43). Extended treatment 
of mice with high-dose VEGF resulted in accumulation of Gr-1+ 
IMCs in the BM and the periphery (69). In a transgenic mouse 
model of spontaneously occurring melanoma, an increase in 
VEGF correlated with disease progression, MDSC accumulation, 
and immunosuppression (23). Granulocyte colony-stimulating 
factor (G-CSF) or granulocyte–macrophage colony-stimulating 
factor (GM-CSF) secreted by tumors were also shown to drive 
MDSC accumulation, in correlation with increased tumor 
progression and immunosuppression. Head and neck cancer 
patients with G-CSF producing tumors had increased infiltrates 
of suppressive CD34+ immature myeloid progenitors along with 
a reduced antitumor immune response (70). In a mouse model 
of spontaneous breast cancer, GM-CSF has been described as the 
main tumor-derived factor driving MDSC accumulation (71). 
GM-CSF is a potent adjuvant for vaccination since it is crucial 
for recruitment and activation of APCs. However, it has been 
shown that at a high dose, not only vaccination efficacy is lost but 
also MDSCs accumulate and induce immunosuppression (72). 
Moreover, additional soluble factors secreted by tumors were 
reported to affect MDSC survival and accumulation as shown 
for multiple myeloma cell factors that are able to induce MDSC 
generation through Mcl-1 upregulation (73) (Figure 1G).
Cancer-Associated inflammation induces 
MDSC Accumulation
In addition to tumor-derived factors, the inflammatory environ-
ment of the tumor also provides signals for MDSCs. IL-1, IL-6, 
and TNF-α are secreted in the inflammatory settings of cancer 
and induce immune cell proliferation, survival, activation, and 
infiltration of the tumor to execute the antitumor immune 
response. These mediators have been shown to take a crucial 
part in initiation and progression of colitis-associated cancer, 
hepatocellular carcinoma, and chemical-induced carcinogenesis 
(3, 74–77). Moreover, overexpression of IL-1 was shown to induce 
gastric inflammation and colon cancer, mobilizing MDSCs into 
the inflamed colon (78). We have identified TNFα to serve as 
a key signal for MDSC differentiation arrest, activation, and 
accumulation. In particular, chronically inflamed TNF-α−/− 
mice had reduced MDSC accumulation with low levels of ROS 
and NO− production along with a milder T-cell dysfunction. 
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Treatment of chronically inflamed mice with etanercept (a 
soluble TNF-α receptor) also diminished MDSC number and 
activity, recuperating T-cell function. Addition of TNF-α and 
GM-CSF to MDSC cultures blocked their differentiation toward 
DCs and macrophages compared to addition of GM-CSF alone 
(18). Cyclooxygenase-2 (COX-2) is overexpressed in many types 
of solid tumors and hematological malignancies. Prostaglandin 
E2 (PGE2) produced by this enzyme supports proliferation and 
survival of tumor cells by a direct interaction and serve as a 
key inflammatory mediator. PGE2 drives cell proliferation and 
cytokine production, contributing to overall inflammation. 
In the case of colon cancer, COX-2 activity has been shown to 
increase production of angiogenic factors and correlated with 
immunosuppression mediated by Tregs (79, 80). Targeting of 
COX-2 in 4T1 mouse mammary carcinoma resulted in reduced 
MDSC accumulation and relief of NK dysfunction, compared to 
control 4T1, when transplanted in healthy host mice (81). A PGE2 
controlled mechanism was recently described, inducing produc-
tion of CXCL12 (SDF-1) in the tumor microenvironment and 
expression of CXCR4 on MDSCs, mediating their recruitment in 
human ovarian cancer (82) (Figure 1G to A).
iMMUNe MONiTORiNG AND COMBATiNG 
MDSCs TO eNHANCe ANTiCANCeR 
TReATMeNT eFFiCACY
Immunosuppression is evident in many cases of cancer patients. 
Elevated MDSC levels with enhanced suppressive features 
inversely correlate with CD247 expression and the immune func-
tion of T- and NK-cells in the tumor site and peripheral blood, as 
shown for colon cancer patients (30). Immunosuppression and 
MDSC accumulation correlate with disease severity and provide 
a poor prognosis for the patients. Levels of peripheral blood 
MDSCs and CD247 expression serve as biomarkers capable of 
sensing chronic inflammation and immunosuppression. The 
levels of peripheral blood MDSCs and their suppressive features 
as measured by their production of NO and ROS can indicate 
the cause of the suppressive environment, while CD247 expres-
sion in T-cells is capable of sensing the resulting immunosup-
pression (83). Tracking these biomarkers provides new insights 
and understanding of the immunological effects and efficiency 
of anticancer treatments. Thus, following tumor parameters 
alongside with monitoring the immune system functional prop-
erties could increase anticancer therapy success rates and enable 
designing improved personalized treatments. This strategy holds 
for chemotherapeutic as well as immune-based treatments, as the 
complex dynamics within the tumor micro and macro environ-
ments involving tumor and immune cells will dictate success of 
both types of therapies (Figure 2).
Chemotherapy and immunosuppression
Chemotherapeutic drugs commonly used to treat cancer affect 
not only the tumor but also the immune system, having a crucial 
impact on antitumor responses and disease outcome. Although 
chemotherapies combat the tumors and lead to their regression, 
the effects on the tumor microenvironment and the immune 
system are not clearly understood. Kanterman et al. have recently 
shown that different chemotherapeutic agents have adverse effects 
on MDSC accumulation and immunosuppression (30). While 
treatment of colitis-induced cancer in mice with 5-fluorouracil 
(5FU) diminished tumor load, MDSC levels, and immunosup-
pression, the topoisomerase-1 inhibitor CPT-11 (irinotecan) 
had the opposite effect, increasing tumor load, MDSC levels, 
and immunosuppression. FOLFIRI and FOLFOX are two com-
monly used regimens in treating colon cancer patients, and until 
recently, their effect on the immune system had not been taken 
into account when choosing between them. Administration 
of FOLFIRI, containing irinotecan in combination with 5FU, 
leads to increased accumulation of MDSCs and CD247 down-
regulation. In contrast, the FOLFOX regimen, which contains 
oxaliplatin instead of irinotecan, leads to lower levels of MDSCs 
and recovery of CD247. Moreover, MDSCs in FOLFIRI-treated 
patients are more active, as indicated by increased production of 
NO and ROS (30). It is important to note that it is still unknown 
whether oxaliplatin, which is included in the FOLFOX regimen, 
has a direct effect on MDSCs. Another study showed that low-
dose cyclophosphamide (CP) therapy that induces immunogenic 
tumor cell death and decreases Treg numbers had no beneficial 
antimelanoma effects. Instead, it increased accumulation of 
MDSCs, which exhibited elevated suppressive activity. Thus, 
melanoma therapy with low-dose CP could be efficient only when 
combined with the neutralization of MDSC immunosuppressive 
function and chronic inflammatory microenvironment (84). The 
cumulative data emphasize the importance of immune monitor-
ing when choosing a chemotherapeutic treatment, as conventional 
measurements of chemotherapeutic effects on the tumor only are 
insufficient to evaluate their curative effectiveness. Moreover, as 
some conventional chemotherapies display significant immuno-
therapeutic effects, they could be used in combination with the 
new generation of immune-based and targeted therapies.
immune-Based Therapy and 
immunosuppression
Activating the immune system has emerged as a promising way 
to treat cancer, and numerous new immune-based treatments are 
currently under investigation for the treatment of cancer. Recent 
successful phase III clinical trials of therapeutic cancer vaccines 
include the FDA-approved sipuleucel-T prostate cancer vac-
cine, melanoma peptide vaccines, and personalized lymphoma 
vaccines (85). Furthermore, two immune checkpoint inhibitors 
(anti-PD1 and anti-CTLA4) have reignited enthusiasm for the 
development of immunotherapeutic drugs for cancer, having 
demonstrated high response rates and prolonged overall survival 
in cancer patients (86). However, tumor-induced immunosup-
pression limits the potency of several standard and novel thera-
peutic interventions, which require a functional immune system 
or an environment that supports immune responses. All these 
therapies, as promising as they may be, risk a high probability to 
fail when immunosuppressive environment mediated by MDSCs 
is evident.
Cancer vaccines are based on presentation of tumor antigens 
by autologous DCs to resident T-cells in order to enhance 
antitumor cytotoxic activity. Dysfunctional T-cells evident in a 
FiGURe 2 | Clinical implications of immune monitoring in cancer patients. Monitoring of patient’s immune status in a blood sample may provide invaluable 
insight and help design better treatment regimens. The level of circulating MDSCs indicates how suppressive the environment is, while the expression of CD247 in 
circulating T-cells senses the suppression directly. Patients who have low MDSCs and high CD247 expression have a better prognosis and are more likely to 
respond to treatment (competent), as there are less MDSCs to support the tumor’s growth and the immune system is functional (lower part). On the other hand, 
high MDSC levels and low CD247 expression indicate a suppressive protumorigenic environment and immunosuppression (upper part), providing a poor prognosis 
(non-competent). Immune monitoring can be used when choosing a chemotherapeutic drug for treatment (right panel). Drugs such as cyclophosphamide and 
irinotecan induce MDSC accumulation and generate a harmful suppressive environment, while 5FU and oxaliplatin alleviate the harmful settings. Low MDSCs and 
high CD247 indicate immune competence making the patient a good candidate for immune-based therapy, while in suppressed and non-competent patients 
immune-based therapy is likely to fail. Suppressed patients may benefit from anti-MDSC treatment (left panel): MDSC elimination with chemotherapy (gemcitabine 
and 5FU); induction of differentiation (ATRA); blocking the signals leading to MDSC accumulation (etanercept-blocking TNF-α, anti-GM-CSF, Avastin-blocking VEGF, 
specific tyrosine kinase inhibitor-CSF-1R inhibitor, and Celecoxib-COX-2 inhibitor); and inhibition of MDSC activity (nitroaspirin-blocking ARG-1/iNOS and 
sildenafil-blocking PDE-5). Success of anti-MDSC treatment could be measured by immune monitoring, as MDSC levels drop and CD247 expression recovers, 
making the patient immune competent and suitable for immune-based therapy.
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tumor-associated immunosuppressive environment will abrogate 
the efficacy of such treatments. Moreover, several studies have 
reported difficulties to generate mature DCs ex vivo when the 
prevalence of CD14+ HLA-DR−/low MDSCs was high in the initial 
samples taken from non-Hodgkin lymphoma, prostate cancer, 
and glioblastoma (87–90). Ex vivo expansion of TILs allows intro-
duction of high numbers of tumor-reactive cytotoxic CD8+ T-cell 
clones back to the patient. Mok et al. have shown that the suppres-
sion generated by MDSCs reduces the efficacy of such treatments 
and that blocking CSF-1R (M-CSF receptor) reduces MDSC 
levels and restores the desired cytotoxic activity (91). Immune 
checkpoint-targeted therapy with anti-PD1 and anti-CTLA-4, 
which are aimed at inducing increased endogenous T-cell activity, 
require functional T-cells. Such treatments are expected to fail if 
MDSC suppressive activity is evident. Indeed, melanoma patients 
who had low level of MDSCs were more likely to respond to anti-
CTLA-4 treatment (92, 93). Determining the patient’s immune 
status and immunosuppression prior to treatment can predict the 
likelihood to respond to such immune-based therapies.
Combating the Tumor and 
immunosuppressive environment
The immunosuppression detected in chronic inflammation is a 
reversible phenomenon. Eliminating MDSCs by inducing their 
differentiation, inhibiting inflammatory signals that lead to their 
accumulation, or blocking their suppressive activity may lead to 
alleviation of chronic inflammation and restoration of immune 
functions. Various drugs and compounds, some of which are FDA 
approved, have been shown to target MDSCs in mouse models, 
attenuating chronic inflammation and inhibiting tumor growth 
(18, 94). Elimination of MDSCs is easily done in mice by using 
anti-Gr1 (RB6-8C5) monoclonal antibody (18); however, no 
specific markers in human MDSCs are utilized in such a manner 
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so far. Nevertheless, gemcitabine and 5FU have been shown to 
specifically eliminate MDSCs by inducing apoptosis in mouse 
models and human patients (30, 95, 96). All-trans retinoic acid 
(ATRA) can potently induce MDSC differentiation into mature 
myeloid cells, which lose the harmful suppressive phenotype (97) 
and improve immune response in cancer patients (98). Blocking 
of various inflammatory signals prevalent in the chronically 
inflamed environment such as TNF-α (18), M-CSF (by block-
ing CSF-1R) (91), GM-CSF (99), and inhibition of COX-2 with 
celecoxib (100) resulted in reduced accumulation of MDSCs and 
decreased tumor load in mouse models. Renal cell carcinoma 
patients treated with bevacizumab (Avastin) to reduce VEGF-
mediated angiogenesis also had reduced numbers of MDSCs in 
the tumors (101). Several drugs have been tested to target MDSC 
suppressive activity. Nitroaspirins have been shown to inhibit 
ARG-1 and reduce NO production and arginine consumption, 
thus correcting immune dysfunction and promoting tumor 
eradication in mice (102). Sildenafil inhibits cyclic GMP-specific 
phosphodiesterase type 5 (PDE-5) in MDSCs and reduces their 
suppressive activity, thus augmenting an antitumor response in 
mice in vivo (103). Sildenafil has also been shown to reduce Treg 
induction by MDSCs in a mouse model of B-cell lymphoma (45). 
Although various modalities capable of combating MDSCs are 
already FDA approved and show great promise in mouse models, 
there is a lack of clinical data regarding the effects of such treat-
ments on MDSCs and chronic inflammation in cancer patients.
CONCLUDiNG ReMARKS
As the immune system and tumor cells intimately interact 
and create a complex and dynamic multifactorial micro and 
macro inflammatory milieu, which eventually supports tumor 
initiation, growth, and invasion, it is mandatory to monitor in 
parallel the tumor features alongside with the immune status. The 
cumulative data depicting the capacity of effector and regulatory 
immune cells to shape the environment toward supporting tumor 
growth highlight the critical role of chronic inflammation and 
associated immunosuppression, mediated by MDSCs, as a major 
obstacle in the success of chemo- and immune-based anticancer 
therapies. Only very recently, it has become clear that in order 
to increase the success rates of anticancer immunotherapies, a 
combination between monitoring the tumor responses and the 
patient’s immune system functionality is critical for the design 
of optimal treatments. Therefore, it is suggested that prior to an 
applied immune-based therapy, the patients must be evaluated 
for their immune status, using biomarkers such as CD247and 
MDSC levels and suppressive features. If immunosuppression is 
detected, it must be combated either by targeting MDSCs or by 
neutralizing the inflammatory environment. Upon recuperation 
of the immune status, immune-based therapies could then be 
applied. Furthermore, as described by various studies includ-
ing ours, changes in the patients’ immune status also occur 
in response to various chemotherapies. As adverse effects of 
chemotherapies were obtained on the immune system function-
ality, some enhancing MDSC-mediated immunosuppression and 
others inhibiting MDSC accumulation and suppressive activity, it 
is mandatory to follow up chemotherapy effects not only on the 
tumors but also on the innate and adaptive immune system arms. 
Combating MDSCs and chronic inflammation, while monitoring 
MDSCs and CD247 in T-cells and NK cells, may provide valuable 
tools for choosing the correct therapeutic regiments and timing 
while taking into account both the cancer and immune factors. 
By combating MDSCs, their direct and indirect harmful effects 
could be alleviated on the one hand and allow reconstitution 
of the immune response on the other hand, thus gaining bet-
ter therapy results. Moreover, monitoring the immune system 
functionality in the course of a given anticancer treatment could 
have an added value on the evaluation of tumor regression or 
progression as chronic inflammation and immunosuppression 
will decrease or increase accordingly. Therefore, by combining 
a monitoring system to follow in parallel changes in tumor and 
immune system function based on the described biomarkers, an 
increase in the efficacy of both immune and non-immune based 
anticancer therapies could be achieved and enable the design of 
optimal personalized treatments.
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